CSS
SLN

Cubist Systematic Strategies’s Silence Therapeutics SLN Stock Holding History

Cubist Systematic Strategies’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,364
Closed -$20.8K – 3474
2025
Q1 		$20.8K Sell
7,364
-98,956
-93% -$483K ﹤0.01% 2746
2024
Q4 		$731K Buy
106,320
+60,015
+130% +$774K ﹤0.01% 1979
2024
Q3 		$842K Buy
46,305
+36,867
+391% +$686K 0.01% 1927
2024
Q2 		$179K Sell
9,438
-26,843
-74% -$571K ﹤0.01% 2531
2024
Q1 		$784K Buy
+36,281
New +$789K ﹤0.01% 2345
2023
Q2 		– Sell
-2,600
Closed -$16.1K – 4241
2023
Q1 		$16.1K Buy
+2,600
New +$30.7K ﹤0.01% 3686
2022
Q4 		– Sell
-500
Closed -$5K – 4568
2022
Q3 		$5K Buy
+500
New +$5.26K ﹤0.01% 4319
2022
Q1 		– Sell
-184
Closed -$4K – 3751
2021
Q4 		$4K Buy
+184
New +$4.26K ﹤0.01% 3412

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Cubist Systematic Strategies's SLN Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Silence Therapeutics (SLN) in Q2 2025, closing a stake of 7,364 shares — an estimated $20.8K sold.

Cubist Systematic Strategies first reported a position in SLN in Q4 2021 and held it in 8 quarters. The position peaked at $842K in Q3 2024. 55 funds tracked by Wall St. Rank hold SLN as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Silence Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 7,364 Silence Therapeutics shares in Q2 2025, an estimated $20.8K.
  • Cubist Systematic Strategies first reported a position in Silence Therapeutics in Q4 2021 and held it in 8 quarters.
  • Cubist Systematic Strategies's Silence Therapeutics position peaked at $842K in Q3 2024.
  • 55 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.